65626-23-5

Usage

Uses

Used in Pharmaceutical Industry:
(TETRAHYDRO-PYRAN-4-YL)-ACETALDEHYDE is used as an intermediate in the synthesis of various pharmaceutical compounds for its ability to facilitate the creation of complex organic molecules. Its role in drug development is crucial, as it can be incorporated into the structures of potential therapeutic agents, enhancing their efficacy and pharmacological properties.
Used in Perfumery Industry:
In the perfumery industry, (TETRAHYDRO-PYRAN-4-YL)-ACETALDEHYDE is used as a fragrance ingredient for its sweet, slightly floral scent. It contributes to the development of unique and complex fragrance profiles, adding depth and nuance to perfume compositions.
Used in Flavorings Industry:
(TETRAHYDRO-PYRAN-4-YL)-ACETALDEHYDE is utilized as a flavoring agent, providing a subtle sweetness and enhancing the taste profiles of various food and beverage products. Its use in flavor creation allows for the development of innovative and appealing taste experiences.
Used in Organic Synthesis:
(TETRAHYDRO-PYRAN-4-YL)-ACETALDEHYDE is used as a building block in organic synthesis for its ability to form a wide range of organic compounds. Its versatility in chemical reactions makes it a valuable component in the development of new materials and chemicals, with potential applications in various industries beyond pharmaceuticals, perfumery, and flavorings.

InChI:InChI=1/C7H12O2/c8-4-1-7-2-5-9-6-3-7/h4,7H,1-3,5-6H2

Upstream product

• 85064-61-5 2-(tetrahydro-2H-pyran-4-yl)acetic acid 
• 130312-00-4 ethyl tetrahydro-4H-pyran-4-ylideneacetate 
• 103260-44-2 ethyl tetrahydropyran-4-acetate 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 4677-18-3 2-(tetrahydropyran-4-yl)-ethanol 

Downstream Products

• 1607458-03-6 benzyl 3-(4-(2-oxoethyl)tetrahydro-2H-pyran-4-yl)-2-phenylpropanoate 
• 1380805-57-1 (2S,3R,4S,5R)-4-(3-chloro-2-fluoro-phenyl)-3-(4-chloro-2-fluoro-phenyl)-2-(2,2-dimethyl-propyl)-5-hydroxymethyl-1-[2-(tetrahydro-pyran-4-yl)-ethyl]-pyrrolidine-3-carbonitrile 

Relevant academic research and scientific papers

Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 Inhibitors

ATAD2 is a cancer-associated protein whose bromodomain has been described as among the least druggable of its class. In our recent disclosure of the first chemical probe against this bromodomain, GSK8814 (6), we described the use of a conformationally constrained methoxy piperidine to gain selectivity over the BET bromodomains. Here we describe an orthogonal conformational restriction strategy of the piperidine ring to give potent and selective tropane inhibitors and show structural insights into why this was more challenging than expected. Greater understanding of why different rational approaches succeeded or failed should help in the future design of selectivity in the bromodomain family.

DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions co

Dihydropyrrolopyridine inhibitors of ROR-gamma

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions co

HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME

Disclosed are compounds of formula (I): or a pharmaceutically acceptable salt thereof; wherein Y, Ra, Ra', Rc, Rf, X2, Rd, Rd', Re, Re', m, and G have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry, useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular and neurodegenerative diseases or disorders.

AZAINDOLE GLUCOKINASE ACTIVATORS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

New high affinity H3 receptor agonists without a basic side chain

In this study, we replaced the basic amine function of the known histamine H3 receptor agonists imbutamine or immepip with non-basic alcohol or hydrocarbon moieties. All compounds in this study show a moderate to high affinity for the cloned human H3 receptor and, unexpectedly, almost all of them act as potent agonists. Moreover, in the alcohol series, we consistently observed an increased selectivity for the human H3 receptor over the human H4 receptor, but none of the compounds in this series possess increased affinity and functional activity compared to their alkylamine congeners. In this new series of compounds VUF5657, 5-(1H-imidazol-4-yl)-pentan-1-ol, is the most potent histamine H3 receptor agonist (pKi = 8.0 and pEC50 = 8.1) with a 320-fold selectivity at the human H3 receptor over the human H 4 receptor.